{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T08:58:15Z","timestamp":1770627495941,"version":"3.49.0"},"reference-count":16,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100010174","name":"University of Colorado","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010174","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Vet Pharm &amp; Therapeutics"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The objective of this study was to evaluate the pharmacokinetics of the standard cytarabine (Ara\u2010C) protocol (50\u00a0mg\/m<jats:sup>2<\/jats:sup> subcutaneously every 12\u00a0hr for 2\u00a0days) used for dogs with neuroinflammatory disease and compare it to two more practical protocols (a single 200\u00a0mg\/m<jats:sup>2<\/jats:sup> subcutaneous dose and two 100\u00a0mg\/m<jats:sup>2<\/jats:sup> subcutaneous doses every 12\u00a0hr). Four client\u2010owned dogs previously diagnosed with meningoencephalomyelitis of unknown origin were administered three distinct Ara\u2010C protocols with a 21\u2010day washout between each protocol. A complete blood count was performed seven days after each dosing protocol to assess for clinically relevant myelosuppression. No adverse events were observed. Plasma Ara\u2010C concentrations were measured using a validated liquid chromatography coupled to tandem mass spectrometry assay. The mean maximal concentrations in this study were 4,230, 9,293, and 16,675\u00a0ng\/ml for a single dose of 50, 100, and 200\u00a0mg\/m<jats:sup>2<\/jats:sup>, respectively. There was a linear relationship between dose and drug exposure. Drug exposure was similar regardless of the dosing protocol when the total dose was analyzed, with an area under the concentration versus time curve of 37,026, 38,465, and 32,510\u00a0ng\u00a0\u00d7\u00a0hr\/ml for 50, 100, and 200\u00a0mg\/m<jats:sup>2<\/jats:sup>, respectively.<\/jats:p>","DOI":"10.1111\/jvp.12809","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T13:12:00Z","timestamp":1567775520000},"page":"588-592","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The pharmacokinetics of cytarabine administered at three distinct subcutaneous dosing protocols in dogs with meningoencephalomyelitis of unknown origin"],"prefix":"10.1111","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9394-7193","authenticated-orcid":false,"given":"Aslynn","family":"Jones","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences Colorado State University Fort Collins CO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"McGrath","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences Colorado State University Fort Collins CO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel L.","family":"Gustafson","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences Colorado State University Fort Collins CO"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,9,6]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870715)60:2<165::AID-CNCR2820600207>3.0.CO;2-G"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(93)90444-2"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cvsm.2014.07.009"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.12008"},{"key":"e_1_2_8_6_1","first-page":"319","volume-title":"New treatments for granulomatous meningoencephalomyelitis","author":"Cuddon P. A.","year":"2002"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511527081","volume-title":"The cancer chemotherapy handbook","author":"Fischer D. S.","year":"2003"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2009.03.031"},{"key":"e_1_2_8_9_1","first-page":"309","article-title":"Pharmacologic studies of cyclocytidine and \u2010arabinosylcytosine in dogs","volume":"3","author":"Ho D. H. W.","year":"1975","journal-title":"Drug Metabolism and Disposition"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.162.8.241"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.12667"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(92)90022-R"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00686329"},{"key":"e_1_2_8_14_1","first-page":"653","article-title":"Influence of Fludarabine on Pharmacokinetics and Pharmacodynamics of Cytarabine: Implications for a continuous infusion schedule","volume":"2","author":"Seymour J. F.","year":"1996","journal-title":"Clinical Cancer Research."},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-68761-7_15"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.100878"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-5827.2006.00172.x"}],"container-title":["Journal of Veterinary Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvp.12809","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvp.12809","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvp.12809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T22:52:30Z","timestamp":1694213550000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvp.12809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,6]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1111\/jvp.12809"],"URL":"https:\/\/doi.org\/10.1111\/jvp.12809","archive":["Portico"],"relation":{},"ISSN":["0140-7783","1365-2885"],"issn-type":[{"value":"0140-7783","type":"print"},{"value":"1365-2885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,6]]},"assertion":[{"value":"2019-01-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}